These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 31819517)
1. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Tella SH; Mahipal A; Kommalapati A; Jin Z Onco Targets Ther; 2019; 12():10335-10342. PubMed ID: 31819517 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113 [TBL] [Abstract][Full Text] [Related]
3. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Cersosimo RJ Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092 [TBL] [Abstract][Full Text] [Related]
5. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Tella SH; Kommalapati A; Mahipal A; Jin Z Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326 [TBL] [Abstract][Full Text] [Related]
6. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Weinmann A; Galle PR Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209 [TBL] [Abstract][Full Text] [Related]
7. A concise review of the changing landscape of hepatocellular carcinoma. Draper A Am J Manag Care; 2020 Oct; 26(10 Suppl):S211-S219. PubMed ID: 33052638 [TBL] [Abstract][Full Text] [Related]
8. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Feng MY; Chan LL; Chan SL Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172 [TBL] [Abstract][Full Text] [Related]
9. Molecular therapies for HCC: Looking outside the box. Faivre S; Rimassa L; Finn RS J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496 [TBL] [Abstract][Full Text] [Related]
10. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. Sun W; Cabrera R J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759 [TBL] [Abstract][Full Text] [Related]
11. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525 [TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126 [TBL] [Abstract][Full Text] [Related]